Unmet potential of Generics and Biosimilars to reduce healthcare costs

Author(s): Professor Philip D Walson, MD

The high cost of pharmaceuticals has been gaining increasing attention as a threat to both healthcare systems and patients’ access to care globally. This GaBI issue contains articles focusing on the fact that generics and follow-on biologicals have yet to achieve their potential to mitigate these costs in most if not all countries. In an […]

Read more →